Literature DB >> 26484925

Sensitivity of Neuropsychological Tests to Identify Cognitive Decline in Highly Educated Elderly Individuals: 12 Months Follow up.

Odelia Elkana1,2, Osnat Reichman Eisikovits1, Noga Oren2,3,4, Vered Betzale3, Nir Giladi3, Elissa L Ash2,3,5.   

Abstract

Highly educated individuals have a lower risk of developing dementia and Alzheimer's disease (AD). A common assumption is that their "cognitive reserve" protects them from cognitive decline and postpones the clinical manifestation of dementia. These highly educated individuals usually obtain normal scores on cognitive screening tests, although at the same time they can experience subjective cognitive decline and difficulty in multiple cognitive domains. Although comprehensive neuropsychological evaluations usually identify subtle changes in cognition, they demand extensive resources and thus are expensive and difficult to obtain. Therefore, lack of sensitivity of screening tests on the one hand, along with difficulty to acquire a comprehensive neuropsychological evaluation on the other hand, impede identification of cognitive decline at its earliest stages in this special population. Accordingly, this study aims to identify which neuropsychological tests have the highest sensitivity to detect the earliest stages of cognitive decline among highly educated elderly [n = 27, ages 66-80 (mean = 72.6 SD = 4.54), mean education level = 17.14 (SD = 3.21 range: 12-24 years)]. Baseline scores and scores at one-year follow up were obtained. We also conducted MRI scans to characterize the relation between brain volume and cognitive performance. Results show significant reductions in RVALT, Semantic verbal Fluency, ROCF copy, and MoCA scores whereas PF, TMT, ROCF delay, digit span, and knowledge tests were not significant. The study stresses the importance of using sensitive neuropsychological tests to examine this special population and the need to create norms that combine an individual's education with age.

Entities:  

Keywords:  Cognitive decline; cognitive reserve; elderly; high education; magnetic resonance imaging; mild cognitive impairment; neuropsychological testing

Mesh:

Year:  2016        PMID: 26484925     DOI: 10.3233/JAD-150562

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Mild cognitive impairment and structural brain abnormalities in a sexagenarian with a history of childhood traumatic brain injury.

Authors:  John Darrell Van Horn; Andrei Irimia; Carinna M Torgerson; Avnish Bhattrai; Zachary Jacokes; Paul M Vespa
Journal:  J Neurosci Res       Date:  2017-05-20       Impact factor: 4.164

2.  The cognitive impact of guard shifts in physicians: a before-after study.

Authors:  Cristina Benítez-Provedo; Blanca Talavera; David García-Azorín; Alberto Marcos-Dolado
Journal:  Neurol Sci       Date:  2021-08-18       Impact factor: 3.307

3.  Using data science to diagnose and characterize heterogeneity of Alzheimer's disease.

Authors:  Ting F A Ang; Ning An; Huitong Ding; Sherral Devine; Sanford H Auerbach; Joseph Massaro; Prajakta Joshi; Xue Liu; Yulin Liu; Elizabeth Mahon; Rhoda Au; Honghuang Lin
Journal:  Alzheimers Dement (N Y)       Date:  2019-06-27

Review 4.  Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.

Authors:  Federico Rodriguez-Porcel; Kathryn A Wyman-Chick; Carla Abdelnour Ruiz; Jon B Toledo; Daniel Ferreira; Prabitha Urwyler; Rimona S Weil; Joseph Kane; Andrea Pilotto; Arvid Rongve; Bradley Boeve; John-Paul Taylor; Ian McKeith; Dag Aarsland; Simon J G Lewis
Journal:  Transl Neurodegener       Date:  2022-05-02       Impact factor: 9.883

5.  Visual Attention Performances and Related Cerebral Microstructural Integrity Among Subjects With Subjective Cognitive Decline and Mild Cognitive Impairment.

Authors:  Min-Chien Tu; Chung-Ping Lo; Ching-Feng Huang; Wen-Hui Huang; Jie Fu Deng; Yen-Hsuan Hsu
Journal:  Front Aging Neurosci       Date:  2018-09-07       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.